PubMed · 2004 · 34 citations · 22 references
MedicineOncologyPathologyBreast OncologyImmunotherapyMolecular OncologyCancer BiomarkersCancer ImmunotherapyHer2-positive Breast CancerImmuno-oncology BiomarkersImmunotherapy For Breast CancerTumor MarkersBreast Cancer HistopathologyBreast Cancer Response AssessmentHistopathological ResponseNeoadjuvant Her2-targeted TherapyNeoadjuvant Therapy MonitoringPilot Study DesignSerum Tumor MarkersTumor Marker Monitoring
BACKGROUND: This prospective pilot study was performed to elucidate whether early changes in serum levels of the Her-2/neu extracellular domain (ECD) reflect histopathological response to trastuzumab-based neoadjuvant therapy in patients with Her-2/neu-overexpressing breast cancer. PATIENTS AND METHODS: ECD levels were measured throughout neoadjuvant trastuzumab-based treatment in 16 patients using a Her-2/neu Microtiter ELISA. RESULTS: In 9 (56%) patients with Her-2/neu shedding tumors (ECD > 15 ng/ml), ECD values (in % of baseline) of non-responders vs. responders were 117% vs. 55% on day 8 (p=0.014), 157% vs. 58% on day 22 (p=0.061) and 114% vs. 46% at restaging (p=0.049). CONCLUSION: Serial monitoring of serum Her-2/neu ECD levels may represent a valuable tool to predict pathological response to trastuzumab-based neoadjuvant therapy in patients with Her-2/neu-overexpressing tumors.
22
Bernard Fisher, A Brown, E.P. Mamounas et al. · Journal of Clinical Oncology · 1997 · 1.8K citations